Virtus Biotech ETF (BBP) Volatility Skew
Implied volatility skew shows how IV varies across strike prices for a given expiration. Steeper skews indicate higher demand for downside protection relative to upside speculation.
Virtus Biotech ETF (BBP) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $36.3M, listed on AMEX, carrying a beta of 0.80 to the broader market. The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index, which tracks the performance of biotechnology companies with at least one drug therapy approved by the FDA. public since 2014-12-17.
Snapshot as of May 15, 2026.
- Spot Price
- $86.93
- ATM IV
- 25.9%
- IV Skew 25Δ
- 0.052
- IV Rank
- 25.5%
- IV Percentile
- 57.9%
- Term Structure Slope
- -0.004
As of May 15, 2026, Virtus Biotech ETF (BBP) at-the-money implied volatility is 25.9%. IV rank is 25.5% (where 0% is the 52-week low and 100% is the 52-week high). IV percentile is 57.9%. The 25-delta skew is +0.052: calls carry premium over puts, indicating upside speculation or squeeze risk. High IV rank typically favors premium-selling strategies; low IV rank favors premium-buying.
BBP Strategy Selection at Current Volatility Levels
For Virtus Biotech ETF options at 25.9% ATM IV, low IV rank (25.5%) favors premium-buying or long-vol structures: long calls or puts, debit spreads, calendar spreads, long straddles. The risk: low-rank regimes can persist for months while time decay eats premium-buyers alive. The 25-delta skew tilts to calls, so call-credit spreads or covered-call writes harvest more premium than put-credit spreads of the same width. Pair the vol-rank read with the dealer-gamma view and the upcoming-events calendar to confirm the strategy fits both the structural regime and the path-dependent risk. The variance risk premium - the persistent gap between implied and subsequently realized vol - is positive in equity markets on average; high IV rank typically reflects a stretch where the premium is wider than usual.
Learn how volatility skew is reported and how to read the data →
Frequently asked BBP volatility skew questions
- What is the current BBP ATM implied volatility?
- As of May 15, 2026, Virtus Biotech ETF (BBP) at-the-money implied volatility is 25.9%. IV rank is 25.5% on a 0-100% scale anchored to the 1-year IV range. ATM IV is the volatility input that makes a Black-Scholes-equivalent model reproduce the listed at-the-money option prices.
- Is BBP IV high or low historically?
- IV is subdued relative to its 1-year history, conditions that typically favor premium-buying strategies (long calls, long puts, debit spreads, calendar spreads).
- What does BBP volatility skew tell options traders?
- Volatility skew is the pattern by which IV varies across strikes for a given expiration. Virtus Biotech ETF shows upside-skewed pricing: 25-delta calls trade richer than 25-delta puts, often reflecting upside speculation or squeeze risk. Skew matters for risk-defined strategy selection: when downside puts are rich, put-credit spreads capture more premium; when upside calls are rich, call-credit spreads or covered-call writes harvest more.